Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis
Name:
B Guinn Application of the pMHC ...
Size:
9.357Mb
Format:
PDF
Description:
Main article
Authors
Brooks, Suzanne E.Bonney, Stephanie A.
Lee, Cindy
Publicover, Amy
Khan, Ghazala
Smits, Evelien L.J.
Sigurdardottir, Dagmar
Arno, Matthew
Li, Demin
Mills, Ken I.
Pulford, Karen
Banham, Alison H.
van Tendeloo, Viggo
Mufti, Ghulam J.
Rammensee, Hans-Georg
Elliott, Tim J.
Orchard, Kim H.
Guinn, Barbara-Ann
Issue Date
2015-10-22
Metadata
Show full item recordAbstract
Immunotherapy treatments for cancer are becoming increasingly successful, however to further improve our understanding of the T-cell recognition involved in effective responses and to encourage moves towards the development of personalised treatments for leukaemia immunotherapy, precise antigenic targets in individual patients have been identified. Cellular arrays using peptide-MHC (pMHC) tetramers allow the simultaneous detection of different antigen specific T-cell populations naturally circulating in patients and normal donors. We have developed the pMHC array to detect CD8+ T-cell populations in leukaemia patients that recognise epitopes within viral antigens (cytomegalovirus (CMV) and influenza (Flu)) and leukaemia antigens (including Per Arnt Sim domain 1 (PASD1), MelanA, Wilms’ Tumour (WT1) and tyrosinase). We show that the pMHC array is at least as sensitive as flow cytometry and has the potential to rapidly identify more than 40 specific T-cell populations in a small sample of T-cells (0.8–1.4 x 106). Fourteen of the twenty-six acute myeloid leukaemia (AML) patients analysed had T cells that recognised tumour antigen epitopes, and eight of these recognised PASD1 epitopes. Other tumour epitopes recognised were MelanA (n = 3), tyrosinase (n = 3) and WT1126-134 (n = 1). One of the seven acute lymphocytic leukaemia (ALL) patients analysed had T cells that recognised the MUC1950-958 epitope. In the future the pMHC array may be used provide point of care T-cell analyses, predict patient response to conventional therapy and direct personalised immunotherapy for patients.Citation
Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, et al. (2015) Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis 2015, 10 (10):e0140483 PLOS ONEPublisher
Public Library of ScienceJournal
PLOS ONEPubMed ID
26492414PubMed Central ID
PMC4619595Additional Links
http://dx.plos.org/10.1371/journal.pone.0140483Type
ArticleLanguage
enISSN
1932-6203Sponsors
This work was supported by Cancer Research U.K. (SEB, SAB)(http://www.cancerresearchuk.org/), a European Group for Blood and Marrow Transplant fellow (CL) (https://www.ebmt.org/Contents/Pages/Default.aspx), Leukaemia and Lymphoma Research (BG)(https://leukaemialymphomaresearch.org.uk/), Cork Cancer Research Centre (BG)(http://www.ccrc.ie/), Wellcome Value in People award (BG) (http://www.wellcome.ac.uk/Funding/Public-engagement/Funding-schemes/People-Awards-and-Society-Awards/), British Society for Haematology (BG) (http://www.b-s-h.org.uk/), the Wessex Cancer Trust (BG) (http://wessexcancer.org.uk/), and Research Foundation Flanders (ELS) (http://www.fwo.be/en/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0140483
Scopus Count
Collections
The following license files are associated with this item:
Related articles
- An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.
- Authors: Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, Pulford K, Mufti G, Stevenson F, Guinn BA
- Issue date: 2013
- [MHC tetramers: tracking specific immunity].
- Authors: Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D
- Issue date: 2003
- A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias.
- Authors: Knights AJ, Weinzierl AO, Flad T, Guinn BA, Mueller L, Mufti GJ, Stevanovic S, Pawelec G
- Issue date: 2006 Jun
- Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
- Authors: Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S
- Issue date: 2005 Jun 15
- Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia.
- Authors: Westermann J, Lessen A, Schlimper C, Baskaynak G, le Coutre P, Dörken B, Pezzutto A
- Issue date: 2006 Jan